In this regard, a well-studied pathway is the oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT) and mammalian target of rapamycin (mTOR) which interact with AR promoting PCa development and impact the response to PI3K-AT-mTOR-targeted therapies (de Bono et al., 2019). This evidence concerns the gene AR and posterior cortical atrophy.